Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-term safety of secukinumab in pooled data from 28 cli...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Alice B. Gottlieb, Atul Deodhar, Iain B. Mcinnes, Xenofon Baraliakos, Kristian Reich, Stefan Schreiber, Weibin Bao, Kwaku Marfo, Hanno B. Richards, Luminita Pricop, Abhijit Shete, Vivek Trivedi, Deborah Keefe, Charis C. Papavassilis, Piotr Jagiello, Philemon Papanastasiou, Philip J. Mease, Mark Lebwohl
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Medical Journals Sweden 2022-04-01
Sarja:Acta Dermato-Venereologica
Aiheet:
Ankylosing spondylitis
biologics
interleukin
psoriasis
psoriatic arthritis
safety
Linkit:https://medicaljournalssweden.se/actadv/article/view/563

Internet

https://medicaljournalssweden.se/actadv/article/view/563

Samankaltaisia teoksia